Velaglucerase alfa: A new option for gaucher disease treatment

Drugs of Today

Volumn 47, Issue 7, 2011, Pages 515-529

  Zimran, Ari ^a  

^a SHAARE ZEDEK MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; IMIGLUCERASE; TALIGLUCERASE ALFA; VELAGLUCERASE ALFA;

AMINO ACID SUBSTITUTION; ANEMIA; BACKACHE; BODY TEMPERATURE; BONE DENSITY; BONE PAIN; CELL INTERACTION; CLINICAL PROTOCOL; CRYSTAL STRUCTURE; DIZZINESS; DOSE RESPONSE; DRUG APPROVAL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MARKETING; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG SUBSTITUTION; DRUG SYNTHESIS; DRUG TISSUE LEVEL; DRUG TOLERABILITY; DRUG USE; DRUG WITHDRAWAL; ENDOCYTOSIS; ENZYME ACTIVITY; ENZYME KINETICS; ENZYME REPLACEMENT; EUROPE; GAUCHER DISEASE; GENE ACTIVATION; GENE MUTATION; HEALTH CARE ACCESS; HEALTH PROGRAM; HEMATOLOGICAL PARAMETERS; HEMOGLOBIN BLOOD LEVEL; HOME CARE; HUMAN; IMMUNOGENICITY; ISRAEL; LIVER WEIGHT; MAXIMUM PLASMA CONCENTRATION; MIGRAINE; MULTICENTER STUDY (TOPIC); NAUSEA; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEROCONVERSION; SIDE EFFECT; SKIN ALLERGY; SPLEEN WEIGHT; THROMBOCYTE COUNT; TREATMENT OUTCOME;

ANIMALS; CLINICAL TRIALS AS TOPIC; GAUCHER DISEASE; GLUCOSYLCERAMIDASE; HUMANS;

EID: 80052805118     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2011.47.7.1608922     Document Type: Review

References (65)

1. Vellodi, A. Lysosomal storage disorders. Br J Haematol 2005, 128(4): 413-31.
2. Staretz-Chacham, O., Lang, T.C., LaMarca, M.E., Krasnewich, D., Sidransky, E. Lysosomal storage disorders in the newborn. Pediatrics 2009, 123(4): 1191-207.
3. Beutler, E., Grabowski, G.A. Gaucher disease. In: The Metabolic and Molecular Bases of Inherited Diseases. 8th ed. C.R. Scriver et al. (Eds.). McGraw-Hill: New York 2001, 3635-68.
4. Jmoudiak, M., Futerman, A.H. Gaucher disease: pathological mechanisms and modern management. Br J Haematol 2005, 129(2): 178-88.
5. Chen, M., Wang, J. Gaucher disease: review of the literature. Arch Pathol Lab Med 2008, 132(5): 851-3.
6. Hruska, K.S., LaMarca, M.E., Scott, C.R., Sidransky, E. Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA). Hum Mutat 2008, 29(5): 567-83.
7. Futerman, A.H. Cellular pathology in Gaucher disease. In: Gaucher Disease. A.H. Futerman, A. Zimran (Eds.). Taylor & Francis Group: Boca Raton, FL, USA 2007, 97-108.
8. Mistry, P.K., Liu, J., Yang, M. et al. Glucocerebrosidase genedeficient mouse recapitulates Gaucher disease displaying cellular and molecular dysregulation beyond the macrophage. Proc Natl Acad Sci U S A 2010, 107(45): 19473-8.
9. Sidransky, E. Gaucher disease: complexity in a "simple" disorder. Mol Genet Metab 2004, 83(1-2): 6-15.
10. Eblan, M.J., Goker-Alpan, O., Sidransky, E. Perinatal lethal Gaucher disease: a distinct phenotype along the neuronopathic continuum. Fetal Pediatr Pathol 2005, 24(4-5): 205-22.
11. Charrow, J., Andersson, H.C., Kaplan, P. et al. The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease. Arch Intern Med 2000, 160(18): 2835-43.
12. Wenstrup, R.J., Roca-Espiau, M., Weinreb, N.J., Bembi, B. Skeletal aspects of Gaucher disease: a review. Br J Radiol 2002, 75(Suppl. 1): A2-A12.
13. Deduve, C. From cytases to lysosomes. Fed Proc 1964, 23: 1045-9.
14. Barton, N.W., Brady, R.O., Dambrosia, J.M. et al. Replacement therapy for inherited enzyme deficiency - macrophage-targeted glucocerebrosidase for Gaucher's disease. N Engl J Med 1991, 324(21): 1464-70.
15. Food and Drug Administration. Approved drug products with therapeutic equivalence evaluations. p. 41; 30th Edition. http://www.fda.gov/downloads/ Drugs/DevelopmentAppr ovalProcess/UCM071436.pdf. Accessed November 11, 2010.
16. Pastores, G.M. Recombinant glucocerebrosidase (imiglucerase) as a therapy for Gaucher disease. BioDrugs 2010, 24(1): 41-7.
17. Food and Drug Administration. Approved drug products with therapeutic equivalence evaluations. p. 242; 30th Edition. http://www.fda.gov/downloads/ Drugs/Develop mentApprovalProcess/UCM071436.pdf. Accessed November 11, 2010.
18. Grabowski, G.A., Barton, N.W., Pastores, G. et al. Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources. Ann Intern Med 1995, 122(1): 33-9.
19. Shaaltiel, Y., Bartfeld, D., Hashmueli, S. et al. Production of glucocerebrosidase with terminal mannose glycans for enzyme replacement therapy of Gaucher's disease using a plant cell system. Plant Biotechnol J 2007, 5(5): 579-90.
20. Zimran, A., Loveday, K., Fratazzi, C., Elstein, D. A pharmacokinetic analysis of a novel enzyme replacement therapy with Gene-Activated human glucocerebrosidase (GA-GCB) in patients with type 1 Gaucher disease. Blood Cells Mol Dis 2007, 39(1): 115-8.
21. Moran, N. Shire's replacement enzymes validate gene activation. Nat Biotechnol 2010, 28(11): 1139-40.
22. European Medicines Agency. European Public Assessment Report for VPRIV. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Public-assessment- report/human/001249/WC500096489.pdf. Accessed January 25, 2011.
23. Brumshtein, B., Salinas, P., Peterson, B. et al. Characterization of gene-activated human acid-β-glucosidase: crystal structure, glycan composition, and internalization into macrophages. Glycobiology 2010, 20(1): 24-32.
24. Dvir, H., Harel, M., McCarthy, A.A., Toker, L., Silman, I., Futerman, A.H., Sussman, J.L. X-ray structure of human acid-β-glucosidase, the defective enzyme in Gaucher disease. EMBO Rep 2003, 4(7): 704-9.
25. Xu, Y.H., Sun, Y., Barnes, S., Grabowski, G.A. Comparative therapeutic effects of velaglucerase alfa and imiglucerase in a Gaucher disease mouse model. PLoS One 2010, 5(5): e10750.
26. Kornfeld, S. Trafficking of lysosomal enzymes in normal and disease states. J Clin Invest 1986, 77(1): 1-6.
27. Grabowski, G.A., Kacena, K., Cole, J.A. et al. Dose-response relationships for enzyme replacement therapy with imiglucerase/alglucerase in patients with Gaucher disease type 1. Genet Med 2009, 11(2): 92-100.
28. Hollak, C.E., de Fost, M., van Dussen, L., Vom Dahl, S., Aerts, J.M. Enzyme therapy for the treatment of type 1 Gaucher disease: clinical outcomes and dose - response relationships. Expert Opin Pharmacother 2009, 10(16): 2641-52.
29. Zimran, A., Altarescu, G., Philips, M. et al. Phase 1/2 and extension study of velaglucerase alfa replacement therapy in adults with type 1 Gaucher disease: 48-month experience. Blood 2010, 115(23): 4651-6.
30. Mehta, A., Ben Dridi, M.F., Gonzalez, D.E. et al. A multicenter, randomized, double-blind, head-to-head, phase III study of velaglucerase alfa enzyme replacement therapy compared with imiglucerase in patients with type 1 Gaucher disease. 60th Annu Meet Am Soc Human Genetics (Nov 2-6, Washington, D.C.) 2010, Abst 3068.
31. Giraldo, P., Grabowski, G., Pastores, G. et al. Safety and efficacy of velaglucerase alfa in Gaucher disease type 1 patients previously treated with imiglucerase. Eur Working Group Gaucher Dis - 9th Int Meet (June 30-July 3, Cologne) 2010, Abst O31.
32. Zimran, A., Gonzalez, D., Lukina, E., Ben-Dridi, M.-F., Kisinovsky, I., Crombez, E., Bhirangi, K. Enzyme replacement therapy with velaglucerase alfa significantly improves key clinical parameters in type 1 Gaucher disease: positive results from a randomized, double-blind, global, phase III study. Mol Genet Metab 2010, 99(2): S41.
33. Steinbrook, R. Drug shortages and public health. N Engl J Med 2009, 361(16): 1525-7.
34. Zimran, A., Gonzalez, D., Crombez, E., Bhirangi, K. Enzyme replacement therapy with velaglucerase alfa improves key clinical parameters in a pediatric subgroup with type 1 Gaucher disease. Mol Genet Metab 2010, 99(2): S40-S1.
35. Grabowski, G., Pastores, G., Mardach, R. et al. Safety & efficacy of velaglucerase alfa in type 1 Gaucher disease patients previously treated with imiglucerase. Southeast Reg Genetics Group - 28th Annu Meet (July 22-24, Ponte Vedra Beach) 2010.
36. Elstein, D., Foldes, A.J., Zahrieh, D., Cohn, G.M., Djordjevic, M., Brutaru, C., Zimran, A. Significant and continuous improvement in bone mineral density among type 1 Gaucher disease patients treated with velaglucerase alfa: 69-month experience, including dose reduction. Blood Cells Mol Dis 2011, 47(1): 56-61.
37. Elstein, D., Zimran, A., Cohn, G.M., Bhirangi, K. Five-year safety and efficacy of velaglucerase alfa in type 1 Gaucher disease experience in clinic and home settings. Mol Genet Metab 2010, 99(2): S18.
38. Pastores, G.M., Weinreb, N.J., Aerts, H. et al. Therapeutic goals in the treatment of Gaucher disease. Semin Hematol 2004, 41(4, Suppl. 5): 4-14.
39. Elstein, D., Cohn, G.M., Wang, N., Djordjevic, M., Brutaru, C., Zimran, A. Early achievement and maintenance of the therapeutic goals using velaglucerase alfa in type 1 Gaucher disease. Blood Cells Mol Dis 2011, 46(1): 119-23.
40. Zimran, A., Hollak, C.E., Abrahamov, A., van Oers, M.H., Kelly, M., Beutler, E. Home treatment with intravenous enzyme replacement therapy for Gaucher disease: an international collaborative study of 33 patients. Blood 1993, 82(4): 1107-9.
41. Oz, A., Arbel, N., Shapiro, D., Greenberg, Y., Zimran, A. Home infusions provide a convenient option for intravenous enzyme replacement therapy with velaglucerase alfa in patients with type 1 Gaucher disease. Eur Working Group Gaucher Dis - 9th Int Meet (June 30-July 3, Cologne) 2010, Abst P33.
42. Zimran, A., Lukina, E.A., Ben Dridi, M.-F. et al. Enzyme replacement therapy with velaglucerase alfa significantly improves key clinical parameters in type 1 Gaucher disease: positive results from a randomized, double-blind, global, phase III study. 15th Cong Eur Hematol Assoc (June 10-13, Barcelona) 2010, Abst 0188.
43. Koren, E., Smith, H.W., Shores, E. et al. Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products. J Immunol Methods 2008, 333(1-2): 1-9.
44. Hunt, S.V. Perspectives from B cell immunology: fact and fancy. Int J Clin Pharmacol Ther 2009, 47(Suppl. 1): S86-S99.
45. Brooks, D.A. Immune response to enzyme replacement therapy in lysosomal storage disorder patients and animal models. Mol Genet Metab 1999, 68(2): 268-75.
46. Brady, R.O., Murray, G.J., Oliver, K.L., Leitman, S.F., Sneller, M.C., Fleisher, T.A., Barton, N.W. Management of neutralizing antibody to Ceredase in a patient with type 3 Gaucher disease. Pediatrics 1997, 100(6): E11.
47. Ponce, E., Moskovitz, J., Grabowski, G. Enzyme therapy in Gaucher disease type 1: effect of neutralizing antibodies to acid β-glucosidase. Blood 1997, 90(1): 43-8. (Pubitemid 27276545)
48. Richards, S.M., Olson, T.A., McPherson, J.M. Antibody response in patients with Gaucher disease after repeated infusion with macrophage-targeted glucocerebrosidase. Blood 1993, 82(5): 1402-9.
49. Rosenberg, M., Kingma, W., Fitzpatrick, M.A., Richards, S.M. Immunosurveillance of alglucerase enzyme therapy for Gaucher patients: induction of humoral tolerance in seroconverted patients after repeat administration. Blood 1999, 93(6): 2081-8.
50. Zhao, H., Bailey, L.A., Grabowski, G.A. Enzyme therapy of Gaucher disease: clinical and biochemical changes during production of and tolerization for neutralizing antibodies. Blood Cells Mol Dis 2003, 30(1): 90-6.
51. Ruiz, J., Barzegar, S., Clarke, A. et al. Differences in immunogenic response in patients receiving velaglucerase alfa compared with imiglucerase treatment using equivalent methods. Annu Clin Genetics Meet (March 24-28, Albuquerque) 2010, Abst 139.
52. Hollak, C.E., vom Dahl, S., Aerts, J.M. et al. Force majeure: therapeutic measures in response to restricted supply of imiglucerase (Cerezyme) for patients with Gaucher disease. Blood Cells Mol Dis 2010, 44(1): 41-7.
53. Zimran, A., Altarescu, G., Elstein, D. Nonprecipitous changes upon withdrawal from imiglucerase for Gaucher disease because of a shortage in supply. Blood Cells Mol Dis 2011, 46(1): 111-4.
54. Giraldo, P., Irun, P., Alfonso, P. et al. Evaluation of Spanish Gaucher disease patients after a 6-month imiglucerase shortage. Blood Cells Mol Dis 2011, 46(1): 115-8.
55. Shire presents positive data for patients with type 1 Gaucher disease who switched to VPRIVTM [news release]. Shire Human Genetic Therapies Inc., March 25, 2010. http://www.shire.com/shireplc/uploads/press/VPRIVACMG- PressRelease-25Mar2010.pdf. Accessed September 14, 2010.
56. Shire Human Genetic Therapies Inc. Velaglucerase alfa (GAGCB) Treatment Protocol: HGT-GCB-058 Amendment 2. 2010.
57. Reinke, J., Mengel, E., Beck, M. Efficacy and tolerability of velaglucerase in the treatment of 7 patients with type 1 Gaucher disease - first observations. Eur Working Group Gaucher Dis - 9th Int Meet (June 30-July 3, Cologne) 2010, Abst P38.
58. Milligan, A., Baker, R., Cooke, J., Hughes, D.A., Richfield, L.B., Steel, L., Mehta, A.B. Velaglucerase as enzyme replacement therapy in type 1 Gaucher disease: reporting the first UK non-trial patient. Eur Working Group Gaucher Dis-9th Int Meet (June 30-July 3, Cologne) 2010, Abst P29.
59. Hughes, D.A., Morris, E., Richfield, L., Milligan, A., Cox, T.M., Mehta, A.B., Deegan, P.B. United Kingdom experience of 38 adult Gaucher patients switched to enzyme replacement therapy with velaglucerase alfa as a result of the international imiglucerase shortage. Eur Working Group Gaucher Dis - 9th Int Meet (June 30-July 3, Cologne) 2010, Abst O15.
60. Shire completes submission of NDA for velaglucerase alfa for Type 1 Gaucher disease and reports positive results for remaining two phase III trials [news release]. Shire Human Genetic Therapies Inc., September 1, 2009. http://www.shire.com/shireplc/uploads/press/FINALvela ph3NDAapproved083109.pdf. Accessed November 11, 2010.
61. FDA grants priority review for Shire's velaglucerase alfa for type 1 Gaucher disease [news release]. Shire Human Genetic Therapies Inc., November 4, 2009. http://www.shire. com/shireplc/uploads/press/velapriorityreviewFinal04 Nov09.pdf. Accessed September 14, 2010.
62. Shire announces FDA approval of VPRIV™ (velaglucerase alfa for injection) for the treatment of type 1 Gaucher disease [news release]. Shire Human Genetic Therapies Inc., February 26, 2010. http://www.shire.com/shireplc/ uploads/press/VPRIV-FDA-ApprovalRelease-26-Feb20 2010.pdf. Accessed September 14, 2010.
63. Shire submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the treatment of type 1 Gaucher disease [news release]. Shire Human Genetic Therapies Inc., November 24, 2009. http://www.shire. com/shireplc/uploads/press/VelaEMEAfilingFINAL24Nov 09.pdf. Accessed November 11, 2010.
64. Shire announces European approval of VPRIV® (velaglucerase alfa) for the treatment of type 1 Gaucher disease [news release]. Shire Human Genetic Therapies Inc., August 26, 2010. http://www.shire.com/shireplc/ uploads/press/Shire-VPRIVEUApprovalRelease-26Aug 2010.pdf. Accessed September 14, 2010.
65. Shire Human Genetic Therapies. Enzyme replacement therapy with Replagal. http://www.replagal.co.uk/hcp-replagal.aspx. Accessed January 31, 2011.